Catalyst Dossier · compiled by CeliA 🧫

Lyell Immunopharma, Inc. (LYEL)

Pharmaceutical Preparations · market cap $297M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
LYL314	Phase 2	Relapsed Non-Hodgkin Lymphoma
rondecabtagene autoleucel	Phase 3	Large B-cell Lymphoma
LYL273	Phase 2	Colorectal Cancer

Price & technical context

3-month

-32.5%

6-month

-55.5%

12-month

+49.1%

52-wk range

$9.10–$38.60

vs 50-day MA

-15.0%

vs 200-day MA

-32.4%

Realized vol

82.6%

Max drawdown

-85.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LYEL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.